Table 1 Correlation between clinicopathological features and androgen receptor expression in 177 breast cancers
AR expression in all breast cancers ( n =177) | |||
|---|---|---|---|
Parameters | Positive ( n =126) | Negative ( n =51) | P -value |
Age at operation | |||
⩽56 | 64 (50.8%) | 23 (45.1%) | |
>56 | 62 (49.2%) | 28 (54.9%) | 0.492 |
Menopause | |||
Negative | 52 (41.3%) | 20 (39.2%) | |
Positive | 74 (58.7%) | 31 (60.8%) | 0.801 |
Tumour size | |||
⩽2 cm | 18 (14.3%) | 6 (11.8%) | |
>2 cm | 108 (85.7%) | 45 (88.2%) | 0.657 |
Lymph node status | |||
Negative | 33 (26.2%) | 8 (15.7%) | |
Positive | 93 (73.8%) | 43 (84.3%) | 0.134 |
Nuclear grade | |||
1, 2 | 98 (77.8%) | 39 (76.5%) | |
3 | 28 (22.2%) | 12 (23.5%) | 0.851 |
Ki67 | |||
⩽14% | 60 (47.6%) | 14 (27.5%) | |
>14% | 66 (52.4%) | 37 (72.5%) | 0.014 |
Intrinsic subtype | |||
TNBC | 23 (18.3%) | 38 (74.5%) | |
Non-TNBC | 103 (81.7%) | 13 (25.5%) | <0.001 |
Intrinsic subtype | |||
HER2BC | 30 (23.8%) | 6 (11.8%) | |
Non-HER2BC | 96 (76.2%) | 45 (88.2%) | 0.071 |
Intrinsic subtype | |||
HRBC | 73 (57.9%) | 7 (13.7%) | |
Non-HRBC | 53 (42.1%) | 44 (86.3%) | <0.001 |
Pathological response | |||
pCR | 43 (34.1%) | 24 (47.1%) | |
Non-pCR | 83 (65.9%) | 27 (52.9%) | 0.108 |
